Serum Concentration of 25-Hydroxy Vitamin D in Patients with Chronic Plaque Psoriasis: A case control study

Authors

  • Yousuf Abd Mallick Dermatology Unit, The Indus Hospital Karachi, Pakistan. https://orcid.org/0000-0002-8250-3319
  • Ahsun Jiwani Indus Hospital Research Center (IHRC), The Indus Hospital Karachi, Pakistan.

DOI:

https://doi.org/10.36570/jduhs.2020.2.985

Keywords:

Psoriasis, 25-hydroxy vitamin D, Psoriasis Area and Severity Index, Body mass index, Case control study

Abstract

Objective: To determine 25-hydroxy vitamin D levels in patients of chronic plaque psoriasis and to assess any relationship between vitamin D deficiency and other disease parameters.

Methods: This case-control study included 140 subjects (70 with chronic plaque psoriasis and 70 controls), and conducted in out-patient department of Dermatology Unit of The Indus Hospital, Karachi, Pakistan from 12th September 2018 to 18th November 2019. Body mass index (BMI) calculated and 25-hydroxy vitamin D (25-HVD) levels were checked in all subjects. Psoriasis Area and Severity Index (PASI) was calculated in psoriasis patients.

Results: Serum concentration of 25-HVD in psoriasis patients is lower as compared to controls (17.1 ± 9.1 vs 18.3 ± 10.7) but it is not statistically significant (P=0.66). Similarly, age, gender and BMI were not statistically different between cases and controls. On comparative analysis, type I plaque psoriasis patients had more lower levels of 25-HVD (P=0.03), especially those who had disease for < 5 years (P=0.01). Stratified analysis revealed males of type I plaque psoriasis had significantly lower levels of 25-HVD as compared to males from type II group (P=0.003).

Conclusion: 25-HVD levels were almost similar in both cases and controls. There was no significant 25-HVD deficiency found in chronic plaque psoriasis patients, neither any relation with age, gender, BMI or PASI. However, 25-HVD levels were much lower in males, type I cases and with shorter duration of disease.

Downloads

Download data is not yet available.

References

Menter A, Strober BE, KaplanDH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am AcadDermatol 2019;80:1029-72. doi: 10.1016/j.jaad.2018.11.057
2. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am AcadDermatol 2014;70:512-6. doi: 10.1016/j.jaad.2013.11.013
3. Mallick YA. Frequency of thyroid disorders in patients with chronic plaque psoriasis and psoriatic arthritis.J Pak AssocDermatol2019;29:182-7.
4. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-5. doi: 10.1126/science.8178173
5. Orgaz-Molina J, Buendıa-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am AcadDermatol 2012;67:931-8. doi: 10.1016/j.jaad.2012.01.040
6. Martens PJ, Gysemans C, Verstuyf A, Mathieu AC. Vitamin D's effect on immune function. Nutrients 2020;12:1248. doi: 10.3390/nu12051248
7.Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun2017;85:78–97. doi: 10.1016/j.jaut.2017.07.007
8. Al‑Dhubaibi MS. Association between Vitamin D deficiency and psoriasis: an exploratory study. Int J Health Sci 2018;12:33-9.
9. Gouni-Berthold I, Berthold HK. Vitamin D and vascular disease.CurrVascPharmacol2020; (Online ahead of print) doi: 10.2174/1570161118666200317151955
10. Danik JS, Manson JE. Vitamin D and cardiovascular disease.Curr Treat Options Cardiovasc Med 2012;14:414–24. doi: 10.1007/s11936-012-0183-8
11. Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G. Vitamin D deficiency and risk of cardiovascular diseases: a narrative review. ClinHypertens2018;24:9. doi: 10.1186/s40885-018-0094-4
12. Al Mheid I, Quyyumi AA. Vitamin D and cardiovascular disease.J Am CollCardiol 2017;70:89-100. doi: 10.1016/j.jacc.2017.05.031
13. Orgaz-Molina J, Magro-Checa C, Rosales-Alexander JL, Arrabal-Polo MA, Buendia-Eisman A, Raya-Alvarez E, et al. Association of 25-hydroxyvitamin D serum levels and metabolic parameters in psoriatic patients with and without arthritis. J Am AcadDermatol 2013;69:938-46. doi: 10.1016/j.jaad.2013.08.007
14. Wen CP, David-Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 2009;12:497-506. doi: 10.1017/S1368980008002802
15. Gallagher JC, Sai AJ. Vitamin D insufficiency, deficiency, and bone health. J ClinEndocrinolMetab 2010;95:2630-3. doi: 10.1210/jc.2010-0918
16. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-9.
doi: 10.1159/000083509
17. Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G, et al. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 2012;166:505-10.
doi: 10.1111/j.1365-2133.2011.10699.x
18. Maleki M, Nahidi Y, Azizahari S, Meibodi NT, Hadianfar A. Serum 25 OH vitamin D level in psoriatic patients and comparison with control subjects. J Cutan Med Surg 2016;20:207 10.
doi: 10.1177/1203475415622207
19. Srirama L. Serum concentration of 25-hydroxy vitamin D in psoriatic patients in a tertiary care hospital: a case control study. Egypt J DermatolVenerol 2016;36:29-33.
doi: 10.4103/1110-6530.202642
20. Hassab-El-Naby HM, Ibrahim IM, Tahoun AM, Rashad MK. Serum level of vitamin D3 among Egyptian patients with chronic plaque psoriasis vulgaris. Gulf J DermatolVenereol 2016;23:20-6.
21. Zuchi MF, Azevedo PO, Tanaka AA, Schmitt JV, Martins LEAM. Serum levels of 25 hydroxy vitamin D in psoriatic patients. An Bras Dermatol 2015;90:430 2.
doi: 10.1590/abd1806-4841.20153524
22. Ricceri F, Pescitelli L, Tripo L, Prignano F. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. J Am AcadDermatol 2013;68:511-2. doi: 10.1016/j.jaad.2012.10.051
23. Pavlov S, Ivanova I, Gerova D. Vitamin D status in patients with psoriasis. ScrSci Med 2016;48:50-4. doi: 10.14748/ssm.v1i1.1495
24. Solak B, Dikicier BS, Celik HD, Erdem T. Bone mineral density, 25 OH vitamin D and inflammation in patients with psoriasis. PhotodermatolPhotoimmunolPhotomed 2016;32:153 60.doi: 10.1111/phpp.12239
25. Romani J, Caixas A, Carrascosa JM, Ribera M, Rigla M, Luelmo J. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol2012;166:1237-44. doi: 10.1111/j.1365-2133.2012.10883.x
26. Wilson PB. Serum 25 hydroxyvitamin D status in individuals with psoriasis in the general population. Endocrine 2013;44:537 9. doi: 10.1007/s12020-013-9989-8
27. Morimoto S, Yoshikawa K, Fukuo K, Shiraishi T, Koh E, Imanaka S, et al.Inverse relation between severity of psoriasis and serum 1,25 dihydroxy vitamin D level. J DermatolSci 1990;1:277 82. doi: 10.1016/0923-1811(90)90120-3
28. Merola JF, Han J, Li T, Qureshi AA. No association between vitamin D intake and incident psoriasis among US women. Arch Dermatol Res 2014;306:305 7.
doi: 10.1007/s00403-013-1426-6

Downloads

Additional Files

Published

2020-08-30

How to Cite

Mallick, Y. A., & Jiwani, A. (2020). Serum Concentration of 25-Hydroxy Vitamin D in Patients with Chronic Plaque Psoriasis: A case control study. Journal of the Dow University of Health Sciences (JDUHS), 14(2), 47–53. https://doi.org/10.36570/jduhs.2020.2.985

Issue

Section

Original Articles